Literature DB >> 18991182

Pivmecillinam versus sulfamethizole for short-term treatment of uncomplicated acute cystitis in general practice: a randomized controlled trial.

Lars Bjerrum1, Bente Gahrn-Hansen, Per Grinsted.   

Abstract

OBJECTIVE: To investigate whether short-term treatment with pivmecillinam was more effective than sulfamethizole in patients with acute uncomplicated urinary tract infection (UTI).
DESIGN: Randomized controlled trial.
SETTING: General practice, Denmark.
SUBJECTS: Patients (n = 167) with uncomplicated UTI confirmed by positive urine phase-contrast microscopy. MAIN OUTCOME MEASURES: Drug efficacy based on clinical and bacteriological cure.
RESULTS: Urinary symptoms disappeared first in patients treated with pivmecillinam, but after five days there was no significant difference in clinical cure rate between the two antibiotics. At the follow-up visit 7-10 days after initiation of treatment, 95.4% of patients treated with pivmecillinam and 92.6% of patients treated with sulfamethizole had no persistent cystitis symptoms (difference 2.8%, CI -4.5%; 10.0%). Bacteriological cure was observed in 68.8% of patients randomized to pivmecillinam and in 77.9% randomized to sulfamethizole (difference -9.2%, CI -24.7%; 6.3%). Some 26.8% of patients randomized to pivmecillinam experienced a new UTI within 6 months after treatment compared with 18.4% of patients randomized to sulfamethizole (difference 8.4%, CI -4.5%;21.4%). No patients developed septicaemia with urinary pathogens within one year after initial treatment.
CONCLUSION: Patients treated with a three-day regime of pivmecillinam experienced faster relief of symptoms compared with patients treated with a three-day regime of sulfamethizole. Five days after initiation of treatment there was no significant difference in clinical and bacteriological cure between the two antibiotic regimes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18991182      PMCID: PMC3410480          DOI: 10.1080/02813430802535312

Source DB:  PubMed          Journal:  Scand J Prim Health Care        ISSN: 0281-3432            Impact factor:   2.581


  21 in total

1.  [Can we rely on the results of urine microscopy and culture when tests are performed in general practice?].

Authors:  Lars Bjerrum; Per Grinsted; Per Søgaard
Journal:  Ugeskr Laeger       Date:  2002-04-01

2.  [Estimated consequences of the Danish sulfonamide treatment of uncomplicated urinary tract infections].

Authors:  Niels Høiby; Michael Tvede
Journal:  Ugeskr Laeger       Date:  2002-04-22

3.  Treatment failures after antibiotic therapy of uncomplicated urinary tract infections. A prescription database study.

Authors:  Lars Bjerrum; Ram B Dessau; Jesper Hallas
Journal:  Scand J Prim Health Care       Date:  2002-06       Impact factor: 2.581

4.  [Repeat antibiotic prescriptions following treatment with sulfonamide or pivmecillinam. A survey of prescriptions among women aged 15-50 years in the county of Nordjylland].

Authors:  H C Schønheyder; N Thrane; H T Sørensen
Journal:  Ugeskr Laeger       Date:  2001-12-31

5.  Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project.

Authors:  Sven A Ferry; Stig E Holm; Hans Stenlund; Rolf Lundholm; Tor J Monsen
Journal:  Scand J Prim Health Care       Date:  2007-03       Impact factor: 2.581

6.  Not so simple cystitis: how should prescribers be supported to make informed decisions about the increasing prevalence of infections caused by drug-resistant bacteria?

Authors:  P Davey; D Steinke; T MacDonald; G Phillips; F Sullivan
Journal:  Br J Gen Pract       Date:  2000-02       Impact factor: 5.386

Review 7.  Urinary tract infections in adult general practice patients.

Authors:  Eva Hummers-Pradier; Michael M Kochen
Journal:  Br J Gen Pract       Date:  2002-09       Impact factor: 5.386

8.  The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study.

Authors:  Sven A Ferry; Stig E Holm; Hans Stenlund; Rolf Lundholm; Tor J Monsen
Journal:  Scand J Infect Dis       Date:  2004

9.  Urinary concentrations and urine ex-vivo effect of mecillinam and sulphamethizole.

Authors:  M B Kerrn; N Frimodt-Møller; F Espersen
Journal:  Clin Microbiol Infect       Date:  2004-01       Impact factor: 8.067

10.  Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women.

Authors:  L E Nicolle; K S Madsen; G O Debeeck; E Blochlinger; N Borrild; J P Bru; C Mckinnon; B O'Doherty; W Spiegel; F A M Van Balen; P Menday
Journal:  Scand J Infect Dis       Date:  2002
View more
  11 in total

1.  Uncomplicated Bacterial Community-Acquired Urinary Tract Infection in Adults.

Authors:  Jennifer Kranz; Stefanie Schmidt; Cordula Lebert; Laila Schneidewind; Guido Schmiemann; Florian Wagenlehner
Journal:  Dtsch Arztebl Int       Date:  2017-12-15       Impact factor: 5.594

Review 2.  A systematic review of the outcomes reported in the treatment of uncomplicated urinary tract infection clinical trials.

Authors:  Sinead Duane; Claire Beecher; Akke Vellinga; Andrew W Murphy; Martin Cormican; Andrew Smyth; Patricia Healy; Michael Moore; Paul Little; Declan Devane
Journal:  JAC Antimicrob Resist       Date:  2022-03-22

3.  Urinary tract infections in women: etiology and treatment options.

Authors:  Daniele Minardi; Gianluca d'Anzeo; Daniele Cantoro; Alessandro Conti; Giovanni Muzzonigro
Journal:  Int J Gen Med       Date:  2011-04-19

4.  High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.

Authors:  Arne Søraas; Arnfinn Sundsfjord; Silje Bakken Jørgensen; Knut Liestøl; Pål A Jenum
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

5.  The efficacy of pivmecillinam: 3 days or 5 days t.i.d against community acquired uncomplicated lower urinary tract infections - a randomized, double-blinded, placebo-controlled clinical trial study protocol.

Authors:  Filip Jansåker; Niels Frimodt-Møller; Lars Bjerrum; Jenny Dahl Knudsen
Journal:  BMC Infect Dis       Date:  2016-12-01       Impact factor: 3.090

6.  Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled superiority trial.

Authors:  Filip Jansåker; Sara Thønnings; Frederik Boëtius Hertz; Thomas Kallemose; Jan Værnet; Lars Bjerrum; Thomas Benfield; Niels Frimodt-Møller; Jenny Dahl Knudsen
Journal:  EClinicalMedicine       Date:  2019-07-20

7.  Pivmecillinam for Uncomplicated Lower Urinary Tract Infections Caused by Staphylococcus saprophyticus-Cumulative Observational Data from Four Recent Clinical Studies.

Authors:  Filip Jansåker; Marianne Bollestad; Ingvild Vik; Morten Lindbæk; Lars Bjerrum; Niels Frimodt-Møller; Jenny Dahl Knudsen
Journal:  Antibiotics (Basel)       Date:  2019-05-07

8.  Clinical effectiveness and bacteriological eradication of three different Short-COurse antibiotic regimens and single-dose fosfomycin for uncomplicated lower Urinary Tract infections in adult women (SCOUT study): study protocol for a randomised clinical trial.

Authors:  Ana Garcia-Sangenís; Rosa Morros; Mercedes Aguilar-Sánchez; Laura Medina-Perucha; Alfonso Leiva; Joana Ripoll; Mar Martínez-Pecharromán; Cruz B Bartolomé-Moreno; Rosa Magallon Botaya; Jaime Marín-Cañada; José M Molero; Ana Moragas; Amelia Troncoso; Ramon Monfà; Carl Llor
Journal:  BMJ Open       Date:  2021-11-25       Impact factor: 2.692

Review 9.  Mecillinam for the treatment of acute pyelonephritis and bacteremia caused by Enterobacteriaceae: a literature review.

Authors:  Filip Jansåker; Niels Frimodt-Møller; Thomas L Benfield; Jenny Dahl Knudsen
Journal:  Infect Drug Resist       Date:  2018-05-24       Impact factor: 4.003

10.  Prescription of antibiotics for urinary tract infection in general practice in Denmark.

Authors:  Anne Holm; Gloria Cordoba; Rune Aabenhus
Journal:  Scand J Prim Health Care       Date:  2019-01-28       Impact factor: 2.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.